In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential of Monopar Therapeutics Inc’s copper-binding agent, ALXN1840, in treating Wilson’s Disease. Recent animal data presented at the AASLD conference have clarified the mechanism of action of this agent, showing promising results in reducing total body copper in mice and demonstrating a safe excretion process through the biliary system. These findings are crucial as they address key questions from the FDA and support the drug’s efficacy and safety profile.
Monopar is preparing to submit a New Drug Application (NDA) for ALXN1840 in early 2026, with plans to engage with the FDA by the end of 2025. Despite uncertainties in regulatory timelines, the company’s financial position appears robust, with sufficient cash reserves to support ongoing operations. The decision of Alexion/AstraZeneca to out-license ALXN1840, despite positive Phase 3 results, was attributed to a lack of understanding of the drug’s mechanism, which Monopar’s recent data has helped elucidate. These developments collectively underpin Soumit Roy’s optimistic outlook and Buy rating for Monopar Therapeutics Inc.
In another report released on November 14, Raymond James also maintained a Buy rating on the stock with a $123.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MNPR in relation to earlier this year.